Renovorx, Inc. (RNXT) 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of Renovorx, Inc.'s 2025 Annual Meeting of Stockholders held on June 24, 2025. The filing date is June 25, 2025. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Mountain View, CA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Approximately 20,086,518 shares (55% of the 36,551,752 outstanding shares) were present or represented by proxy, constituting a quorum. Stockholders voted on three proposals:
- Proposal 1 (Director Election): All six nominees were elected for one-year terms. Shaun R. Bagai, Ramtin Agah, and Kirsten Angela Macfarlane received over 99% of votes cast. Laurence J. Marton, Una S. Ryan, and Robert J. Spiegel received approximately 75% of votes cast, with significant votes withheld (ranging from 3.27 million to 3.61 million shares).
- Proposal 2 (Incentive Plan Amendment): Stockholders approved amendments to the 2021 Omnibus Equity Incentive Plan. The plan was increased by 913,794 shares (2.5% of outstanding shares) and the annual "evergreen" provision was increased from 3% to 5% of shares outstanding. The proposal passed with 9,056,181 votes for and 4,037,698 votes against.
- Proposal 3 (Auditor Ratification): Stockholders ratified the appointment of Frank, Rimerman + Co. LLP as the independent registered public accounting firm for the year ending December 31, 2025. The proposal passed with 19,131,750 votes for and 949,070 votes against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, or contingencies beyond the standard disclosure of the voting results.
Key Facts for Investor Verification
- Verify the significant vote withholding (approx. 25%) for three of the six director nominees (Marton, Ryan, Spiegel) compared to near-unanimous support for the other three.
- Confirm the impact of the approved 2021 Plan amendment, specifically the increase in the annual share refresh rate from 3% to 5%, on future dilution.
- Review the Company's upcoming financial reports to assess liquidity and cash burn, as no financial metrics were included in this 8-K.